ATM is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BARD1 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA1 is an inclusion eligibility criterion in 3 clinical trials for invasive breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 status and invasive breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (0 open) [3].

BRCA2 is an inclusion eligibility criterion in 3 clinical trials for invasive breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and invasive breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (0 open) [3].

BRIP1 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRIP1 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 15 clinical trials for invasive breast carcinoma, of which 14 are open and 1 is closed. Of the trials that contain ERBB2 status and invasive breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (5 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open) [3].

FANCA is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR4 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and invasive breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51D status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].